Mutations in PTPN11 could lead to a congenital myasthenic syndrome phenotype: a Noonan syndrome case series.

[1]  B. Bartels,et al.  Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2–4 , 2022, Brain communications.

[2]  Julius O. B. Jacobsen,et al.  The RD‐Connect Genome‐Phenome Analysis Platform: Accelerating diagnosis, research, and gene discovery for rare diseases , 2022, Human mutation.

[3]  R. Horvath,et al.  Identification of a novel homozygous synthesis of cytochrome c oxidase 2 variant in siblings with early‐onset axonal Charcot‐Marie‐Tooth disease , 2022, Human mutation.

[4]  H. Lochmüller,et al.  Congenital myasthenic syndrome: Correlation between clinical features and molecular diagnosis , 2021, European journal of neurology.

[5]  A. Słowik,et al.  Neurogranin and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in Alzheimer’s Disease , 2021, Journal of clinical medicine.

[6]  I. Nelson,et al.  INPP5K and SIL1 associated pathologies with overlapping clinical phenotypes converge through dysregulation of PHGDH. , 2021, Brain : a journal of neurology.

[7]  S. Nampoothiri,et al.  Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations , 2020, BMC Medical Genetics.

[8]  B. Gelb,et al.  Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment , 2020, American journal of medical genetics. Part C, Seminars in medical genetics.

[9]  C. Lorson,et al.  AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of Spinal Muscular Atrophy. , 2019, Human molecular genetics.

[10]  Hanns Lochmüller,et al.  Intersection of Proteomics and Genomics to “Solve the Unsolved” in Rare Disorders such as Neurodegenerative and Neuromuscular Diseases , 2018, Proteomics. Clinical applications.

[11]  Hanns Lochmüller,et al.  The beta-adrenergic agonist salbutamol modulates neuromuscular junction formation in zebrafish models of human myasthenic syndromes , 2018, Human molecular genetics.

[12]  R. Zahedi,et al.  In-depth phenotyping of lymphoblastoid cells suggests selective cellular vulnerability in Marinesco-Sjögren syndrome , 2017, Oncotarget.

[13]  T. Kuntzer,et al.  PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain , 2015, BMC Neurology.

[14]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[15]  Zhon-Yin Zhang,et al.  Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations , 2014, Biochemistry.

[16]  S. Perrotta,et al.  LEOPARD syndrome: clinical dilemmas in differential diagnosis of RASopathies , 2014, BMC Medical Genetics.

[17]  J. Carey,et al.  Peripheral muscle weakness in RASopathies , 2012, Muscle & nerve.

[18]  Albert Sickmann,et al.  Systematic and quantitative comparison of digest efficiency and specificity reveals the impact of trypsin quality on MS-based proteomics. , 2012, Journal of proteomics.

[19]  D. Stevenson,et al.  The musculoskeletal phenotype of the RASopathies , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.

[20]  K. Rauen,et al.  Skeletal muscle pathology in Costello and cardio‐facio‐cutaneous syndromes: Developmental consequences of germline Ras/MAPK activation on myogenesis , 2011, American Journal of Medical Genetics. Part C, Seminars in Medical Genetics.

[21]  P. Robinson,et al.  Neurofibromin (Nf1) is required for skeletal muscle development. , 2011, Human molecular genetics.

[22]  B. Gelb,et al.  Noonan syndrome and clinically related disorders. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[23]  Saskia B Wortmann,et al.  Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway , 2011, European Journal of Human Genetics.

[24]  J. Allanson,et al.  Noonan Syndrome: Clinical Features, Diagnosis, and Management Guidelines , 2010, Pediatrics.

[25]  R. Kucherlapati,et al.  A suggested role for mitochondria in Noonan syndrome. , 2010, Biochimica et Biophysica Acta.

[26]  H. Peng,et al.  The function of Shp2 tyrosine phosphatase in the dispersal of acetylcholine receptor clusters , 2008, BMC Neuroscience.

[27]  L. Castagnoli,et al.  Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes. , 2008, Human molecular genetics.

[28]  M. Digilio,et al.  Leopard syndrome , 2008, Orphanet journal of rare diseases.

[29]  R. Hennekam,et al.  LEOPARD syndrome with partly normal skin and sex chromosome mosaicism , 2007, American journal of medical genetics. Part A.

[30]  J. Krieger,et al.  PTPN11 gene analysis in 74 Brazilian patients with Noonan syndrome or Noonan-like phenotype. , 2006, Genetic testing.

[31]  M. Vidaud,et al.  Reduced phosphatase activity of SHP‐2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1 , 2006, FEBS letters.

[32]  Bruce D Gelb,et al.  Noonan syndrome and related disorders: genetics and pathogenesis. , 2005, Annual review of genomics and human genetics.

[33]  G Mortier,et al.  PTPN11 mutations in patients with LEOPARD syndrome: a French multicentric experience , 2004, Journal of Medical Genetics.

[34]  H. Ropers,et al.  Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.

[35]  M. Digilio,et al.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. , 2002, American journal of human genetics.

[36]  Bruce D Gelb,et al.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. , 2002, American journal of human genetics.

[37]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[38]  W. Engel,et al.  Novel Immunolocalization of α‐Synuclein in Human Muscle of Inclusion‐Body Myositis, Regenerating and Necrotic Muscle Fibers, and at Neuromuscular Junctions , 2000, Journal of neuropathology and experimental neurology.

[39]  T. Pawson,et al.  Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp‐2 , 1997, The EMBO journal.

[40]  H. T. ter Laak,et al.  Myopathology in patients with a Noonan phenotype , 1996, Acta Neuropathologica.

[41]  N. Perrimon,et al.  The nonreceptor protein tyrosine phosphatase corkscrew functions in multiple receptor tyrosine kinase pathways in Drosophila. , 1996, Developmental biology.

[42]  J. Livingston,et al.  Insulin Signaling in Mice Expressing Reduced Levels of Syp* , 1996, The Journal of Biological Chemistry.

[43]  B. Neel,et al.  The SH2-containing protein-tyrosine phosphatase SH-PTP2 is required upstream of MAP kinase for early xenopus development , 1995, Cell.

[44]  M. Patton,et al.  Cardiologic Abnormalities in Noonan Syndrome: Phenotypic Diagnosis and Echocardiographic Assessment of 118 Patients , 1993, Journal of the American College of Cardiology.

[45]  J. Keesey.  AAEE minimonograph #33: Electrodiagnostic approach to defects of neuromuscular transmission , 1989, Muscle & nerve.

[46]  J. Opitz,et al.  Noonan syndrome: a review. , 1985, American journal of medical genetics.

[47]  S. Kitsiou-Tzeli,et al.  Phenotypic spectrum of 80 Greek patients referred as Noonan syndrome and PTPN11 mutation analysis: the value of initial clinical assessment , 2011, European Journal of Pediatrics.

[48]  B. Gelb,et al.  Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development. , 2009, Human molecular genetics.

[49]  G D'Hont,et al.  [The Noonan syndrome]. , 1982, Acta oto-rhino-laryngologica Belgica.